Swiss biotech firm NLS Pharma has announced the acquisition of four patents including one linked to an innovative compound the company seeks to develop for the treatment of attention-deficit hyperactivity disorder (ADHD).
ADHD is considered as one of the most frequently monitored developmental syndromes worldwide.
In the US, 6.4 million children aged between 4 and 17 have been diagnosed with ADHD since 2011 and Time magazine has described it as the icon disability of the digital age.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze